



Réseau de cancérologie Rossy

Rossy Cancer Network














## **Overall Thesis Objectives**

- 1. Characterize opioid therapy and the rate of long-term use for hospitalized cancer patients in the one-year post-discharge period
- 2. Identify potential modifiable patient, provider and healthcare system predictors of persistent prescription opioid use
- 3. Determine whether persistent opioid use is associated with increased patient's healthcare utilization and decreased cancer survival




## **Opioid Consumption in Canada**





Standard Daily Opioid Doses Per Million People, 2013–2015




Proportion of prescriptions for strong opioids increased in Canada between 2012 and 2016

Source: Canadian Institute for Health Information



## **Opioid Poisonings and Risk of Hospitalizations**





## **Objectives of Preliminary Analyses**

1. To describe incidence of opioid use for all patients admitted at two tertiary care hospitals in Montreal (2014 – 2016)

2. To estimate the association between opioid use and lisk of adverse health outcomes in the 90-days post discharge





## **Study Design**






**Characteristics of Study Population** 

	Did not Fill an Opioid Rx (n = 1,593)	Filled an Opioid Rx (n = 1,380)
Age at admission Mean (SD)	70.9 (16.2)	67.0 (13.4)
Hospital unit at discharge (n,%) Surgery Internal Medicine	382 (24.0) 1211 (76.0)	1007 (73.0) 373 (27.0)
Medication Use  History of benzodiazepine use (n.%)	30/03/ 15/00	288 (20.9)
History of opioid use (n,%)	251 (15.8)	472 (34.2)
Opioid Rx at discharge (n,%)  Benzodiazepine prescription at discharge (n,%)	286 (17.9) 307 (19.3)	1178 (85.4) 314 (22.8)
<u>Comorbidities</u> Cancer Diagnosis (n,%)	340 (21.3)	576 (41.7)
History of depression and/or psychiatric disorders) (n,%)	371 (23.3)	329 (23.8)
History of substance and/or alcohol abuse (n,%)	127 (7.9)	84 (6.1%)



# Opioid Prescriptions and Dispensations 90 days post-discharge





## **Statistical Analyses**

#### Comorbidities

Cancer Depression/Substance/ **Alcohol Abuse** 

#### **Medication Use**

Anti-psychotics, Benzodiazepines, Opioids **Health care utilization** 

Hospitalizations, ED visits, **Number of Pharmacies**, **Prescribers** 

**Time -varying** opioid exposure

**Current use** 

Continuous duration of use

Cumulative duration of use

ersonal use only COXHAZARDS

**ED** visits/hospital re- admissions





# **Association between Opioid Use and ED visits**

	Events	Crude HR (95% CI)	Adjusted HR (95% CI)
Current Use Non use Use	1287 300	[Ref] 1.13 (0.99 – 1.28)	[Ref] 1.19 (1.03 – 1.39)
Continuous Duration Use Non use <30 days 30-60 days >60 days	1287 269 22 9	1.13 (0.99 – 1.28)  [Ref] 1.05 (0.92 – 1.21) 1.82 (1.19 – 2.79) 3.52 (1.80 – 6.87)	[Ref] 1.15 (0.99 – 1.35) 1.44 (0.93 – 2.24) 2.63 (1.34 – 5.20)
Cumulative Duration Use Non use <30 days 30-60 days >60 days	951 577 43 16	[Ref] 0.90 (0.81 – 0.99) 1.66 (1.22 - 2.28) 1.88 (1.11 - 3.18)	[Ref] 1.15 (0.98 – 1.33) 1.61 (1.15 – 2.26) 1.74 (1.02 – 2.99)



#### **Conclusions**

- Majority of patients using opioids had a cancer diagnosis and were hospitalized for surgery
- Increased risk of ED visits or hospitalizations when comparing opioid use versus no use
  - Increased risk with longer duration of use
- Potential policy implication: re-assess di ration of treatment with opioid use
  - Increase access to pain clinics
  - Access to publicly funded physiotherapy services



#### **Future Directions**

Study Population: patients with a cancer diagnosis

- Characterise opioid use patterns
- Identify provider & organizational characteristics associated with risk of long-term opioid use

  Quantify the impact of subsequent oxioid-related adverse events on patient's healthcare utilization and cancer survival.



